AstraZeneca PLC Cash Flow Conversion Efficiency
AstraZeneca PLC cash flow conversion efficiency. Based on the latest financial reports, AstraZeneca PLC (AZN) has a cash flow conversion efficiency ratio of 0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.89 Billion) by net assets ($50.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AstraZeneca PLC (1990–2025)
Cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of AstraZeneca PLC for real-time trading data and today's change.
AstraZeneca PLC Cash Flow Conversion Ratio Explained
AstraZeneca PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency. Also see AstraZeneca PLC market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Roche Holding AG
SW:ROP
|
0.296x |
|
Toyota Motor Corporation
MX:TMN
|
0.014x |
|
Wells Fargo & Company
NYSE:WFC
|
0.051x |
|
AstraZeneca PLC
F:ZEGA
|
0.112x |
|
Bank of China Limited
SHG:601988
|
0.099x |
|
Texas Instruments Incorporated
NASDAQ:TXN
|
0.150x |
|
Westpac Banking Corporation
AU:WBCPI
|
-0.064x |
|
Shell PLC ADR
NYSE:SHEL
|
0.118x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (1990–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. Review cash generation quality of AstraZeneca PLC to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $48.72 Billion | $14.57 Billion | 0.299x | +3.09% |
| 2024-12-31 | $40.87 Billion | $11.86 Billion | 0.290x | +9.87% |
| 2023-12-31 | $39.17 Billion | $10.35 Billion | 0.264x | -0.20% |
| 2022-12-31 | $37.06 Billion | $9.81 Billion | 0.265x | +74.37% |
| 2021-12-31 | $39.29 Billion | $5.96 Billion | 0.152x | -50.54% |
| 2020-12-31 | $15.64 Billion | $4.80 Billion | 0.307x | +50.87% |
| 2019-12-31 | $14.60 Billion | $2.97 Billion | 0.203x | +9.12% |
| 2018-12-31 | $14.04 Billion | $2.62 Billion | 0.186x | -13.30% |
| 2017-12-31 | $16.64 Billion | $3.58 Billion | 0.215x | -13.54% |
| 2016-12-31 | $16.67 Billion | $4.14 Billion | 0.249x | +38.46% |
| 2015-12-31 | $18.51 Billion | $3.32 Billion | 0.180x | -50.01% |
| 2014-12-31 | $19.65 Billion | $7.06 Billion | 0.359x | +12.89% |
| 2013-12-31 | $23.25 Billion | $7.40 Billion | 0.318x | +9.71% |
| 2012-12-31 | $23.95 Billion | $6.95 Billion | 0.290x | -12.94% |
| 2011-12-31 | $23.47 Billion | $7.82 Billion | 0.333x | -26.96% |
| 2010-12-31 | $23.41 Billion | $10.68 Billion | 0.456x | -19.08% |
| 2009-12-31 | $20.82 Billion | $11.74 Billion | 0.564x | +3.58% |
| 2008-12-31 | $16.06 Billion | $8.74 Billion | 0.544x | +8.11% |
| 2007-12-31 | $14.91 Billion | $7.51 Billion | 0.504x | +0.90% |
| 2006-12-31 | $15.42 Billion | $7.69 Billion | 0.499x | +1.32% |
| 2005-12-31 | $13.69 Billion | $6.74 Billion | 0.493x | +46.52% |
| 2004-12-31 | $14.50 Billion | $4.87 Billion | 0.336x | +30.45% |
| 2003-12-31 | $13.26 Billion | $3.42 Billion | 0.258x | -40.15% |
| 2002-12-31 | $11.23 Billion | $4.83 Billion | 0.431x | +118.92% |
| 2001-12-31 | $13.76 Billion | $2.71 Billion | 0.197x | -19.62% |
| 2000-12-31 | $9.55 Billion | $2.34 Billion | 0.245x | +178.34% |
| 1999-12-31 | $10.34 Billion | $908.55 Million | 0.088x | -57.78% |
| 1998-12-31 | $4.23 Billion | $879.74 Million | 0.208x | +0.95% |
| 1997-12-31 | $3.62 Billion | $747.21 Million | 0.206x | -4.16% |
| 1996-12-31 | $3.66 Billion | $787.75 Million | 0.215x | +11.55% |
| 1995-12-31 | $3.04 Billion | $585.64 Million | 0.193x | -15.95% |
| 1994-12-31 | $2.73 Billion | $625.36 Million | 0.229x | -24.42% |
| 1993-12-31 | $2.32 Billion | $705.58 Million | 0.304x | -75.00% |
| 1992-12-31 | $169.87 Million | $206.27 Million | 1.214x | +120.37% |
| 1991-12-31 | $916.88 Million | $505.22 Million | 0.551x | -53.33% |
| 1990-12-31 | $682.84 Million | $806.30 Million | 1.181x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more